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Abstract
Renal transplantation has emerged as the preferred option for many patients with end-
stage renal failure. While significant progress has been achieved in short-term outcomes,
long-term survival has only marginally improved. Adaptation of immunosuppressive drugs
to the individual needs of every patient at every time point after transplant will be essential to
improve long-term outcomes. Thus, assays are required that detect allograft injury very early,
which implies frequent noninvasive measurements (e.g. in urine or serum). In this review, we
describe important general aspects in urine biomarker discovery using proteomics and dis-
cuss currently published studies. Although proteomics has the potential to provide insights
into complex pathophysiological processes and reveal novel diagnostic biomarkers as well as
therapeutic drug targets, the actual status of urine proteomic activities in renal transplanta-
tion is still far from reaching these ambitious goals.
Copyright © 2008 S. Karger AG, Basel
Current Problems in Renal Transplantation
Although short-term renal allograft survival has continuously improved over
the last two decades and acute clinical rejection episodes have been significantly
reduced, long-term outcome became only marginally better [1, 2]. There are sev-
eral possible interpretations for this contradictory finding. First, due to the grow-
ing gap between the increasing number of patients waiting for a deceased donor
organ and the decreasing availability of organs with excellent quality, more mar-
ginal donors with pre-existing kidney pathologies have been used in recent years
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(i.e. expanded criteria donors). Such organs can provide comparable survival rates
in the short-term, but their inferior mass of functional kidney tissue may limit
longevity. Second, the benefit of fewer clinical rejection episodes may be partially
off-set by side effects of more potent immunosuppression (e.g. drug nephrotoxic-
ity, polyoma BK virus nephropathy). Third, there is still a significant proportion
of patients who have undetected subclinical rejection which damages the allograft
over years. Therefore, adjusting the level of immunosuppression to the individual
patient in order to balance the risk for rejection and overimmunosuppression is
essential to improve long-term allograft survival (fig. 1).
Clearly, the major goal in transplantation is to reduce injuries to the allo-
graft. While pre-existing organ damage cannot be influenced, all other insults
should be limited. The effects of these insults (i.e. ischemia-reperfusion, rejec-
tion, drug-induced nephrotoxicity, infections and hypertension) accumulate
over time and lead to progressive destruction of the allograft (fig. 2) [3, 4].
Several studies have shown that even subtle injuries detectable only by protocol
allograft biopsies are a risk factor for subsequent deterioration of allograft func-
tion and graft loss [5, 6]. Indeed, repeated protocol allograft biopsies would be
advisable for patient management and adaptation of the immunosuppressive
therapy. However, this strategy is hampered by the small but inherent risk of
allograft biopsies (e.g. bleeding, arteriovenous fistula, and infection), the asso-
ciated costs, and the inconvenience for patients. Therefore, noninvasive bio-
markers that allow for early detection of allograft injury and correlate with
allograft histology would be helpful.
Diagnostic Requirements to Improve Patient Management
Currently, noninvasive monitoring of renal allograft relies mainly on mea-
surement of serum creatinine. However, several studies have demonstrated that
Insufficient
immunosuppression
Overdosed
immunosuppression
Clinical and subclinical
rejection
Drug nephrotoxicity
Infections (e.g. polyoma BK-virus)
Hypertension, diabetes
Immune
system
Fig. 1. Balancing the immunosuppression is a key element for successful transplantation.
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serum creatinine is not sensitive enough to detect clinically important allograft
pathologies which can progress to irreversible allograft damage [5, 6].
Therefore, assays are required that detect allograft pathologies before organ
damage is severe enough to impact serum creatinine.
As detailed in figure 2, various insults (e.g. rejection, drug toxicity) can
injure the allograft. In addition, these insults can affect one or more compart-
ments of the allograft (e.g. tubulointerstitial compartment, glomeruli, arteries).
For example, renal allograft rejection can present as tubulointerstitial inflam-
mation (i.e. cellular rejection Banff Ia [7]) or can be restricted to glomeruli and
arteries (i.e. antibody-mediated rejection [7]). Calcineurin inhibitors can lead to
damage of small vessels or the tubulointerstitial compartment. Independent of
the underlying process, the common consequence of the injury is development
of irreversible tubular atrophy, interstitial fibrosis, glomerulosclerosis, and
fibrous intimal thickening of arteries.
Allograft
injury
Tubulointerstitial
compartment
Glomeruli Arteries
Injuries before transplant Injuries after transplant
Brain death
(deceased donor)
Ischemia
Reperfusion injury
Allograft rejection
Drug nephrotoxicity
Infections
(e.g. polyoma BK-virus)
Accelerating factors
(e.g. hypertension, diabetes)
Glomerulosclerosis Fibrous intimal
thickening of arteries
Tubular atrophy and
interstitial fibrosis
Pre-existing
donor kidney damage
Fig. 2. Overview of factors that can lead to allograft injury. These injuries can be
restricted to mainly one compartment of the allograft or can affect all compartments (i.e.
tubulointerstitial compartment, glomeruli, arteries). Independent of the disease causing the
injury, the final common consequence is tubular atrophy, interstitial fibrosis, glomeruloscle-
rosis and fibrous intimal thickening of arteries, which all represent irreversible damage.
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In general, noninvasive biomarkers can be used to monitor the immune
response, to assess tissue injury in the three compartments of the renal allograft,
or to monitor specific diseases (e.g. polyoma BK virus nephropathy). While
immune and injury monitoring have their specific limitations, combining both
may enhance the accuracy of noninvasive monitoring [8].
Concept of an Unbiased Proteomics-Based Approach 
to Develop Novel Biomarkers in Renal Transplantation
Although many noninvasive biomarkers for renal allograft rejection have
been proposed, none has found wide clinical application [8]. This highlights
that the search for biomarkers enhancing noninvasive monitoring beyond serum
creatinine is a difficult task [9]. With the continuously improving proteomic
technology, it becomes possible to screen for novel biomarkers in an unbiased
way on a broad protein level.
An unbiased proteomics-based approach to develop noninvasive biomark-
ers involves four steps: (a) establishment of a reproducible technological plat-
form for analysis and determination of sample-related confounders, (b)
biomarker discovery phase using well-defined clinical phenotypes, (c) bio-
marker validation in a strictly independent sample set, and (d) high-throughput
assay development.
The first step also involves the decision as to which source (i.e. allograft
tissue, serum, urine) for biomarker development will be used. Clearly, allo-
graft tissue offers the potential to analyze the proteins of all cells involved in
the investigated process and is therefore an ideal source for biomarker discov-
ery. However, comparative analysis may be complicated by differences in the
cellular composition of individual biopsies (e.g. percentage of cortex and
medulla) which do not necessarily reflect the process. The use of laser-capture
microdissection to select distinct compartments (e.g. glomeruli, tubules, ves-
sels) can circumvent this confounding factor. Once a potential biomarker has
been detected and identified in the tissue, it has to be measurable in urine or
serum, and these levels have to correlate with the concentrations in the tissue
in order to become a useful noninvasive biomarker. Serum and urine as
sources for biomarker development have the advantage that collection of suf-
ficient material is not a major issue. However, proteomic analysis in serum is
hampered by its complexity. Ten high-abundance proteins (e.g. albumin,
immunoglobulins) account for 95% of the total protein content [10]. These
proteins, which are unlikely to provide any useful information regarding the
allograft, must be removed to allow detection of the remaining lower-abundance
proteins. Urine as a specimen for proteomic analysis may offer some potential
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advantages because (a) it is in direct contact with main targets of rejection and
other harmful processes (i.e. tubular epithelial cells) and (b) it may represent
the whole kidney allograft. However, urine has variable and changing phy-
sicochemical properties (dilution, pH) and cellular components (epithelial
cells, leukocytes, red blood cells), which can affect its protein content [11].
Furthermore, stability of proteins under these changing conditions may be
impaired [12].
As biomarker discovery is often performed with few samples, it is essen-
tial that these samples are carefully selected and that they represent a distinct
and clinically important phenotype, and include equally well-defined control
groups to enhance the significance of the detected biomarkers. In the
biomarker validation step, a larger but clearly independent sample set should
be used. If known biomarkers for the investigated disease/process already
exist, they should be analyzed in parallel to determine the diagnostic value of
the novel biomarker in comparison with existing biomarkers. Most efforts are
currently concentrated in the biomarker discovery phase; however, the valida-
tion phase is critical and only few potential biomarkers have undergone
this step.
Current Status of Proteomic Studies in Renal Transplantation
General Aspects
Currently published proteomic investigations in human renal transplanta-
tion are limited to studies aiming to detect novel urine biomarkers for specific
pathologies (i.e. allograft rejection, polyoma BK virus nephropathy) [13–17].
Urine might be a valuable source for biomarker development of processes pri-
marily affecting the tubulointerstitial compartment (e.g. tubulointerstitial rejec-
tion, polyoma BK virus nephropathy, drug toxicity), because urine is the only
biological fluid that is in direct contact with tubular epithelial cells. In addition,
urine may reflect the whole allograft overcoming the inherent limitation of allo-
graft biopsies to miss focal processes due to sampling error [18, 19]. Indeed,
urine protein analysis might be of particular interest to screen for early and sub-
tle processes targeting the tubulointerstitial compartment.
Although there are several different proteomic platforms, high-throughput
technologies such as surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF MS) [13–15, 17] and capillary elec-
trophoresis coupled to mass spectrometry (CE-MS) [16] were used in all
currently published studies searching for novel urine biomarkers in renal trans-
plantation. Therefore, in the following paragraphs these two platforms will be
described and discussed in more detail, while referring to recently published
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reviews regarding advantages and limitations of other proteomic approaches
[20, 21].
SELDI-TOF MS combines matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS) with surface retentate
chromatography. Specifically, a sample is applied to a chip surface carrying a
functional group (e.g. normal phase, hydrophobic, cation or anion exchange).
After incubation, proteins that do not bind to the surface are removed by a sim-
ple wash step, and bound peptides/proteins are analyzed by mass spectrometry.
This approach reduces the complexity of the sample being analyzed by select-
ing only a subset of the total proteins. Spectra of samples from different groups
(e.g. acute rejection vs. no rejection) can now be analyzed for differences in
their respective proteomes. The advantages of SELDI-TOF MS are its user
friendliness and high-throughput capabilities [11]. The major disadvantages are
a limited sensitivity to detect proteins and a low resolution and mass accuracy
of the generated spectra [8, 22]. Therefore, only a restricted part of the pro-
teome is accessible for analysis by SELDI-TOF MS.
CE-MS combines protein separation by electrophoresis coupled to an elec-
trospray source for on-line mass spectrometric analysis. This platform provides
fast analysis with high resolution and good mass accuracy of peptides/proteins
smaller than 10 kDa. Limitations of CE-MS are the restriction of the investiga-
tion to small proteins and a limited sensitivity to detect proteins because only a
small sample volume can be injected into the capillary. Both SELDI-TOF-MS
and CE-MS were criticized because most detected potential biomarkers were
not identified. Notably, the generated peptide/protein pattern analyzed with
sophisticated bioinformatics can be used itself as a diagnostic assay (protein
pattern diagnostic), or significantly different expressed proteins can be identi-
fied, which allows to develop quantitative, high-throughput assays (i.e. ELISA).
It is unknown at this point which approach (protein pattern diagnostics or pro-
tein identification/ELISA assay development) will reveal more robust diagnos-
tic markers that can be utilized in a clinical setting [23, 24].
Published Studies Using Proteomics in Human Transplantation
Table 1 summarizes all studies published until January 2007. Four research
groups aimed to detect urine proteins associated with renal allograft rejection
(in most cases tubulointerstitial rejection), one group investigated urine pro-
teins associated with polyoma BK virus nephropathy. Although these are two
different pathological processes, both lead to injury in the tubulointerstitial
compartment with a subsequent tissue response, which might be a common fea-
ture. Interestingly, each group found a different set of urinary proteins that are
associated with the investigated process. To understand these apparent discrep-
ancies, one must consider that in each study disease definition, sample collection,
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Table 1. Published studies using proteomics in human renal transplantation
Reference Proteomic Discovery of Use of bio- Peptides/proteins Biomarker Independent Validation
platform bio-markers informatics detected identified validation outcome
for performed
Clarke SELDI-TOF Allograft Yes 6,500, 6,600, 6,700, No No
et al. [13] MS rejection 7,100, 13,400 Da
Schaub SELDI-TOF Allograft No Three peak clusters at Cleaved 2- Yes Biomarker is
et al. MS rejection 5,270–5,550, 7,050- microglobulin confounded by 
[14, 22, 25] 7,360, and 10,530- urine pH
11,100 Da Not specific for 
rejection
Similar performance 
as other tubular injury 
biomarkers
O’Riordan SELDI-TOF Allograft Yes 2,003, 2,802, 4,756, -Defensin 1, No
et al. MS rejection 5,872, 6,990, 19,018, fragment of 1-
[15, 26] 25,665 Da antichymotrypsin
Wittke CE-MS Allograft Yes 16 peptides (5 No Yes 66% correctly 
et al. [16] rejection upregulated): 1,168, classified as rejection
1,707, 2,078, 2,121,
3,359 Da
Jahnukainen SELDI-TOF Polyoma- Partially 5,872, 11,311, 11,929, No No
et al. [17] MS nephropathy 12,727, 13,349 Da
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sample handling, protocol for protein separation/visualization, and data analy-
sis were not identical. This complicates direct comparison of these studies and
highlights the need for some standardization in disease definition, preanalytical
sample handling, and sample analysis.
Using SELDI-TOF MS, O’Riordan et al. [15, 26] found that decreasing
levels of urinary -defensin-1 and increasing levels of a fragment of 1-
antichymotrypsin were associated with renal allograft rejection. Although we
identified a different protein as a potential biomarker for renal allograft rejec-
tion (i.e. cleaved 2-microglobulin), in both studies fragments of a protein were
predictive for the pathology. Low molecular weight fragments of a protein may
simply be waste products that are even less informative than the intact protein
form. However, they may also indicate increased protease activity associated
with the allograft rejection process and may therefore provide important infor-
mation. Clearly, the significance of protein fragments in the urine as biomark-
ers requires thorough investigation of the fragment, the intact protein, the
responsible proteases and factors that activate them.
Protein identification of a potential biomarker is essential for several rea-
sons. First, knowing the protein/peptide can help to understand their pathophys-
iology in the investigated process. Indeed, in our study we identified the
previously detected potential biomarker for tubulointerstitial renal allograft
rejection as cleaved 2-microglobulin. As intact 2-microglobulin is a well-
known biomarker for tubular injury, it became obvious that cleaved 2-
microglobulin was unlikely to be specific for rejection but rather an indicator of
tubular injury [27]. O’Riordan et al. [26] identified -defensin-1 and a frag-
ment of 1-antichymotrypsin as their previously detected biomarkers for renal
allograft rejection, which are both involved in inflammatory processes. The
other three groups have not yet identified their potential biomarkers (table 1)
[13, 16, 17]. The second important reason for protein identification is that it
allows one to select adequate control groups for a subsequent validation study
and to identify major confounding factors (e.g. urine pH, urine cell compo-
nents, high proteinuria).
As already discussed above, validation in an independent sample set is the
next critical step after detection of a potential biomarker. So far, only two of the
five groups have performed a validation study. Wittke et al. [16] used CE-MS to
analyze urines regarding peptide pattern associated with renal allograft rejec-
tion. In a small validation set, they could correctly classify 66% of samples as
rejection. Our group used a validation sample set that was obtained in another
center with refined control groups and side-by-side evaluation of comparable
biomarkers. In fact, we could confirm the prevalence of cleaved 2-microglobulin
in patients with clinical tubulointerstitial rejection and stable transplants with
normal tubular histology. However, the validation study revealed that cleaved
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2-microglobulin is (a) expectedly not specific for rejection, (b) unable to
distinguish normal tubular histology from subclinical tubulointerstitial
rejection, (c) similar to the other investigated biomarkers for tubular injury
(retinol-binding protein, neutrophil-gelatinase-associated lipocalin, and 
1-microglobulin), and (d) confounded by urine pH restricting its clinical use-
fulness [25]. These two studies highlight that validation is a key element in bio-
marker development and that many identified potential biomarkers will not
pass this step.
Conclusions
With the low rejection and high short-term allograft survival rates that have
been achieved in renal transplantation, the focus will shift to improve long-term
outcomes. A major goal will be to tailor immunosuppression to the individual
needs of every patient at every time point to balance risk for rejection and over-
immunosuppression. To achieve this, novel biomarkers are necessary to detect
subtle forms of allograft rejection and allograft injury, and to allow adapting
immunosuppression before irreversible damage to the allograft has occurred.
Unbiased proteomics-based approaches raise the hope to reveal molecular
mechanisms of allograft rejection and injury, which could translate into novel
biomarkers. So far, no biomarker identified by an unbiased proteomics-based
approach has found a clinical application. As detailed above, the currently pub-
lished approaches were restricted to analysis of urine using high-throughput
technology (i.e. CE-MS, SELDI-TOF MS), which can only assess a limited part
of the proteome. The fast and continuous developments in the field of pro-
teomics including more sensitive mass spectrometers with higher mass accu-
racy, differential protein expression technology (e.g. stable isotope labeling),
and analysis of allograft tissue parts selected by laser-capture microdissection
may allow gaining deeper insights into changes of the proteome associated with
renal allograft rejection and/or injury. Eventually, these data may also reveal
potential targets for future drug development.
References
1 Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: have we made sig-
nificant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant
2004;4:1289–1295.
2 Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft
survival despite a marked decrease in acute rejection rates over the most recent era. Am J
Transplant 2004;4:378–383.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
:4
6:
52
 P
M
Schaub/Wilkins/Nickerson 74
3 Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term
outcomes after renal transplantation. N Engl J Med 2002;346:580–590.
4 Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR: The natural history of
chronic allograft nephropathy. N Engl J Med 2003;349:2326–2333.
5 Rush D: Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am
Soc Nephrol 2006;1:138–143.
6 Moreso F, Ibernon M, Goma M, Carrera M, Fulladosa X, Hueso M, et al: Subclinical rejection
associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft
loss. Am J Transplant 2006;6:747–752.
7 Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al: Antibody-
mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection.
Am J Transplant 2003;3:708–714.
8 Schaub S, Wilkins JA, Rush D, Nickerson P: Developing a tool for noninvasive monitoring of
renal allografts. Expert Rev Proteomics 2006;3:497–509.
9 Hewitt SM, Dear J, Star RA: Discovery of protein biomarkers for renal diseases. J Am Soc
Nephrol 2004;15:1677–1689.
10 Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD: Characterization of the
low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096–1103.
11 Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P: Urine protein profiling with sur-
face-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:
323–332.
12 Donaldson MD, Chambers RE, Woolridge MW, Whicher JT: Stability of 1-microglobulin, 2-
microglobulin and retinol binding protein in urine. Clin Chim Acta 1989;179:73–77.
13 Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP: Characterization of renal
allograft rejection by urinary proteomic analysis. Ann Surg 2003;237:660–665.
14 Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, et al: Proteomic-based detection of
urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219–227.
15 O’Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S, et al: Bioinformatic analysis of
the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004;15:3240–3248.
16 Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M, et al: Detection of acute tubu-
lointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am
J Transplant 2005;5:2479–2488.
17 Jahnukainen T, Malehorn D, Sun M, Lyons-Weiler J, Bigbee W, Gupta G, et al: Proteomic analysis
of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol 2006;17:
3248–3256.
18 Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJ: Histopathological
concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of
acute rejection. Transplantation 1995;60:1215–1219.
19 Nicholson ML, Wheatley TJ, Doughman TM, White SA, Morgan JD, Veitch PS, et al: A prospec-
tive randomized trial of three different sizes of core-cutting needle for renal transplant biopsy.
Kidney Int 2000;58:390–395.
20 Baggerman G, Vierstraete E, De Loof A, Schoofs L: Gel-based versus gel-free proteomics: a
review. Comb Chem High Throughput Screen 2005;8:669–677.
21 Steel LF, Haab BB, Hanash SM: Methods of comparative proteomic profiling for disease diagnos-
tics. J Chromatogr B Analyt Technol Biomed Life Sci 2005;815:275–284.
22 Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, et al: Proteomic-Based
Identification of Cleaved Urinary 2-microglobulin as a Potential Marker for Acute Tubular
Injury in Renal Allografts. Am J Transplant 2005;5:729–738.
23 Zolg W: The proteomic search for diagnostic biomarkers: lost in translation? Mol Cell Proteomics
2006;5:1720–1726.
24 Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: oppor-
tunities and potential limitations. Mol Cell Proteomics 2004;3:367–378.
25 Schaub S, Mayr M, Hönger G, Bestland J, Steiger J, Regeniter A, et al: Detection of Subclinical
Tubular Injury after Renal Transplantation: Comparison of Urine Protein Analysis with Allograft
Histopathology. Transplantation 2007; in press.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
:4
6:
52
 P
M
Proteomics in Renal Transplantation 75
26 O’Riordan E, Orlova TN, Podust VN, Chander PN, Yanagi S, Nakazato M, et al: Characterization
of urinary Peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007;7:
930–940.
27 Schardijn GH, Statius van Eps LW: 2-microglobulin: its significance in the evaluation of renal
function. Kidney Int 1987;32:635–641.
Stefan Schaub, MD, MSc
Department for Transplantation Immunology and Nephrology, University Hospital Basel
Petersgraben 4
CH–4031 Basel (Switzerland)
Tel. 41 61 265 4533, Fax 41 61 265 2410, E-Mail schaubs@uhbs.ch
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
:4
6:
52
 P
M
